JP2018509935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509935A5 JP2018509935A5 JP2017567526A JP2017567526A JP2018509935A5 JP 2018509935 A5 JP2018509935 A5 JP 2018509935A5 JP 2017567526 A JP2017567526 A JP 2017567526A JP 2017567526 A JP2017567526 A JP 2017567526A JP 2018509935 A5 JP2018509935 A5 JP 2018509935A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- complex
- peptide
- seq
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 7
- 230000000890 antigenic effect Effects 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229940122985 Peptide agonist Drugs 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 4
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 4
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 241000283070 Equus zebra Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000009813 cataract 31 multiple types Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021059082A JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015000580 | 2015-03-16 | ||
| EPPCT/EP2015/000580 | 2015-03-16 | ||
| EP2015002244 | 2015-11-09 | ||
| EPPCT/EP2015/002244 | 2015-11-09 | ||
| PCT/EP2016/000471 WO2016146260A1 (en) | 2015-03-16 | 2016-03-16 | A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021059082A Division JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509935A JP2018509935A (ja) | 2018-04-12 |
| JP2018509935A5 true JP2018509935A5 (https=) | 2019-03-22 |
| JP6862369B2 JP6862369B2 (ja) | 2021-04-21 |
Family
ID=55066559
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567525A Active JP6882207B2 (ja) | 2015-03-16 | 2016-03-16 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2017567526A Active JP6862369B2 (ja) | 2015-03-16 | 2016-03-16 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2017567527A Active JP6993240B2 (ja) | 2015-03-16 | 2016-03-16 | 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021059082A Active JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021078278A Active JP7190528B2 (ja) | 2015-03-16 | 2021-05-06 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567525A Active JP6882207B2 (ja) | 2015-03-16 | 2016-03-16 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567527A Active JP6993240B2 (ja) | 2015-03-16 | 2016-03-16 | 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021059082A Active JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021078278A Active JP7190528B2 (ja) | 2015-03-16 | 2021-05-06 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US20180133327A1 (https=) |
| EP (4) | EP3270954A1 (https=) |
| JP (5) | JP6882207B2 (https=) |
| KR (2) | KR102212451B1 (https=) |
| CN (1) | CN107428845A (https=) |
| AU (5) | AU2016232657B9 (https=) |
| CA (3) | CA2973747A1 (https=) |
| CL (1) | CL2017002345A1 (https=) |
| CY (1) | CY1122953T1 (https=) |
| DK (3) | DK3270957T3 (https=) |
| EA (1) | EA038049B1 (https=) |
| ES (3) | ES2978792T3 (https=) |
| HR (1) | HRP20200491T1 (https=) |
| HU (3) | HUE066851T2 (https=) |
| IL (2) | IL253416B (https=) |
| LT (1) | LT3270955T (https=) |
| MX (1) | MX2017011796A (https=) |
| NZ (1) | NZ733762A (https=) |
| PH (1) | PH12017501287A1 (https=) |
| PL (3) | PL3270957T3 (https=) |
| PT (2) | PT3270955T (https=) |
| RS (1) | RS60089B1 (https=) |
| SI (1) | SI3270955T1 (https=) |
| WO (5) | WO2016146143A1 (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| PL3429618T3 (pl) | 2016-03-16 | 2024-07-01 | Amal Therapeutics Sa | Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| HUE067838T2 (hu) * | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| WO2018065623A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Immunogenic compounds for cancer therapy |
| CN110022894B (zh) | 2016-10-07 | 2024-01-19 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| AU2017343779A1 (en) * | 2016-10-13 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to CTLA4 blockade in melanoma using a gene expression signature |
| KR101875055B1 (ko) * | 2016-10-19 | 2018-07-06 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| KR102007203B1 (ko) * | 2016-10-20 | 2019-08-05 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| EP3532505A4 (en) * | 2016-10-25 | 2019-12-25 | Urogen Pharma Ltd. | BODY CAVES IMMUNODULATING TREATMENTS |
| AU2018219862B2 (en) * | 2017-02-07 | 2020-09-17 | Nant Holding IP, LLC | Maximizing T-cell memory and compositions and methods therefor |
| WO2018187515A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| US12121573B2 (en) | 2019-07-14 | 2024-10-22 | Tianxin Wang | Methods and agents including STING agonist to treat tumor |
| US11433128B2 (en) * | 2017-04-07 | 2022-09-06 | Tianxin Wang | Cell surface anchoring antigen conjugates to treat cancer |
| WO2018197926A1 (en) * | 2017-04-26 | 2018-11-01 | Robert Penchovsky | Methods for creating novel antibacterial agents using chimeric antisense oligonucleotides |
| JP2020525427A (ja) * | 2017-06-21 | 2020-08-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置するための方法 |
| WO2019134018A1 (en) * | 2018-01-05 | 2019-07-11 | Telethon Kids Institute | Vaccine conjugates and uses thereof |
| CN111918668A (zh) * | 2018-02-16 | 2020-11-10 | 王天欣 | 治疗肿瘤细胞和癌症的方法和药剂 |
| HRP20230007T1 (hr) * | 2018-04-11 | 2023-03-03 | Enterome S.A. | Antigenski peptidi, namijenjeni sprječavanju i liječenju raka |
| JP7370598B2 (ja) * | 2018-05-02 | 2023-10-30 | 国立大学法人 新潟大学 | ペプチド及びその使用 |
| EP3566718A1 (en) | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
| WO2020014471A1 (en) | 2018-07-11 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of agents across the blood-brain barrier |
| US20210290727A1 (en) * | 2018-08-01 | 2021-09-23 | University Of Maryland, Baltimore | MODULATION OF mTORCI ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTION |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020097395A1 (en) | 2018-11-08 | 2020-05-14 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| CN113316590B (zh) | 2018-11-16 | 2025-02-28 | 百时美施贵宝公司 | 抗nkg2a抗体及其用途 |
| KR102351041B1 (ko) * | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| WO2020130546A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 씨엘케이2 단백질 유래 세포막 투과 도메인 |
| WO2020130548A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 쥐피에이티씨에치4 단백질 유래 세포막 투과 도메인 |
| WO2020130547A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 엘알알씨24 단백질 유래 세포막 투과 도메인 |
| CA3126544A1 (en) * | 2019-01-12 | 2020-07-16 | The Methodist Hospital | Self-assembled peptide nanoparticle and use thereof |
| CN109859795A (zh) * | 2019-02-20 | 2019-06-07 | 成都分迪科技有限公司 | 泛素化降解目标蛋白质的数据库 |
| US20220184087A1 (en) * | 2019-03-28 | 2022-06-16 | The Penn State Research Foundation | Methods and compositions relating to treatment of cancer |
| US11339190B2 (en) | 2020-04-21 | 2022-05-24 | Rush University Medical Center | Peptides for the treatment of covid-19 |
| US11667678B2 (en) | 2019-04-21 | 2023-06-06 | Rush University Medical Center | Peptides for the treatment of COVID-19 |
| US12221622B2 (en) | 2019-05-10 | 2025-02-11 | The Regents Of The University Of California | Modified pluripotent cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| EP3827840A1 (en) | 2019-11-29 | 2021-06-02 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Teipp peptide variant and uses thereof |
| CN115279400B (zh) * | 2020-01-10 | 2026-04-28 | 布里格姆妇女医院 | 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物 |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| KR102484312B1 (ko) * | 2020-05-14 | 2023-01-02 | 한국화학연구원 | 고효능 사스 코로나바이러스 2 항원 및 이를 포함하는 백신 조성물 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| WO2021246666A1 (ko) * | 2020-06-04 | 2021-12-09 | 가톨릭대학교 산학협력단 | 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 항암제 조성물 |
| CA3183774A1 (en) * | 2020-06-26 | 2021-12-30 | National Breast Cancer Coalition | Breast cancer vaccine |
| MX2023002884A (es) | 2020-09-14 | 2023-03-31 | Boehringer Ingelheim Int | Vacuna heterologa de estimulo primario. |
| KR102556731B1 (ko) * | 2020-09-29 | 2023-07-21 | 주식회사 젠센 | 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물 |
| JP2023545178A (ja) * | 2020-10-14 | 2023-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ |
| WO2022087018A1 (en) * | 2020-10-19 | 2022-04-28 | G1 Therapeutics, Inc. | Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer |
| CN113817677B (zh) * | 2021-09-29 | 2023-08-18 | 四川大学 | 泛酸或其衍生物与α-D-葡萄糖-1,6-二磷酸或其衍生物在促进DC迁移中的用途 |
| WO2023059687A1 (en) * | 2021-10-06 | 2023-04-13 | Whispergenics, Inc. | Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of cancers |
| KR102514849B1 (ko) * | 2021-10-28 | 2023-03-28 | 전남대학교산학협력단 | 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물 |
| WO2023174998A1 (en) | 2022-03-16 | 2023-09-21 | Boehringer Ingelheim International Gmbh | Tumor antigens, compounds comprising the tumor antigens kras, tpx2 or aurka and uses thereof |
| CA3247422A1 (en) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERS |
| FR3143031A1 (fr) * | 2022-12-08 | 2024-06-14 | Université Grenoble Alpes | Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles |
| WO2024197792A1 (en) * | 2023-03-31 | 2024-10-03 | Beijing University Of Chinese Medicine | A complex comprising a cell penetrating peptide and a copi sorting inhibitor and uses thereof |
| WO2025262719A1 (en) * | 2024-06-21 | 2025-12-26 | Centre For Dna Fingerprinting And Diagnostics | A composition for treating cancer, methods and use thereof |
| CN119925590A (zh) * | 2025-04-08 | 2025-05-06 | 北京华诺泰生物医药科技有限公司 | 一种mpl复合佐剂及其制备方法和应用 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| FR2728904B1 (fr) | 1995-01-04 | 1997-03-14 | Pasteur Institut | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| IL151097A0 (en) | 2000-02-23 | 2003-04-10 | Smithkline Beecham Biolog | Tumour-specific animal proteins |
| AU2002220265A1 (en) | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| AUPR593101A0 (en) | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| GB0218821D0 (en) | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| WO2005039632A1 (en) * | 2003-10-15 | 2005-05-06 | Istituto Superiore di Sanità | Colorectal cancer antigen |
| US20080305120A1 (en) | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| ES2523172T3 (es) * | 2005-02-04 | 2014-11-21 | Survac Aps | Vacuna de péptido de survivina |
| ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| KR101523391B1 (ko) | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| HRP20150820T1 (xx) * | 2007-07-27 | 2015-09-11 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv neuronskih tumora i tumora mozga |
| RU2010107199A (ru) | 2007-07-31 | 2011-09-10 | Дзе Джонс Хопкинс Юниверсити (Us) | Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| BRPI0911604A2 (pt) * | 2008-04-25 | 2015-12-15 | Inst Systems Biology | vacinas de polipeptídeo de flagelina |
| ES2532896T5 (es) | 2008-05-14 | 2018-03-20 | Immatics Biotechnologies Gmbh | Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan |
| EP3156069B8 (en) | 2008-06-20 | 2020-10-21 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR101040281B1 (ko) | 2008-08-22 | 2011-06-10 | 가톨릭대학교 산학협력단 | Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
| US8074880B2 (en) | 2008-12-01 | 2011-12-13 | Research In Motion Limited | Method, system and mobile device employing enhanced fingerprint authentication |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US9707285B2 (en) | 2009-03-16 | 2017-07-18 | Turnstone Limited Partnership | Vaccination methods |
| MX2011012623A (es) | 2009-05-27 | 2011-12-14 | Glaxosmithkline Biolog Sa | Construcciones de casb7439. |
| BR112012007875A2 (pt) | 2009-07-31 | 2016-11-22 | Medarex Inc | anticorpos totalmente humanos para btla |
| CA2772204A1 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| EP2476440B1 (en) * | 2009-09-11 | 2017-08-02 | Proyecto de Biomedicina Cima, S.L. | Therapeutic compositions for the treatment of hpv-induced diseases |
| US9127077B2 (en) | 2009-09-23 | 2015-09-08 | L'universite Paris Descartes | Polypeptides and nucleic acids for treating ErbB2-dependent cancers |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9175048B2 (en) | 2010-04-26 | 2015-11-03 | Universite Joseph Fourier | Use of peptides as transporters intended for the internalization of molecules of interest into target cells |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| CA2809362C (en) | 2010-08-24 | 2020-03-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| WO2012035558A2 (en) * | 2010-09-14 | 2012-03-22 | Council Of Scientific & Industrial Research | A synthetic immunogen useful for generating long lasting immunity and protection against pathogens |
| WO2012048190A1 (en) * | 2010-10-08 | 2012-04-12 | Regents Of The University Of Minnesota | Annexin ii compositions and methods |
| KR101760464B1 (ko) * | 2010-10-13 | 2017-07-24 | 사회복지법인 삼성생명공익재단 | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 |
| WO2012097012A1 (en) | 2011-01-10 | 2012-07-19 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
| US9187534B2 (en) | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| US8795678B2 (en) * | 2011-05-13 | 2014-08-05 | Academia Sinica | TLR-2 agonists and methods of use thereof |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| US8819679B2 (en) | 2011-07-28 | 2014-08-26 | International Business Machines Corporation | Methods and systems for on-boarding applications to a cloud |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| PE20141937A1 (es) * | 2011-11-16 | 2014-12-18 | Amgen Inc | Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013120073A1 (en) * | 2012-02-09 | 2013-08-15 | Av Therapeutics, Inc. | Synthetic toll-like receptor-4 (tlr-4) agonist peptides |
| RU2650709C2 (ru) | 2012-07-13 | 2018-04-17 | С-Таргет Терапевтикс Гмбх | Иммунорегуляторная вакцина |
| EP2895499B1 (en) | 2012-09-13 | 2019-04-10 | Université de Genève | Cell penetrating peptides |
| PL2897620T3 (pl) | 2012-09-21 | 2020-11-02 | Intensity Therapeutics, Inc | Sposób leczenia nowotworu złośliwego |
| US20150290306A1 (en) * | 2012-10-29 | 2015-10-15 | David E. Anderson | Compositions and methods for diagnosis and treatment of malignant gliomas |
| AU2014248711A1 (en) * | 2013-03-13 | 2015-09-10 | Neostem Oncology, Llc | Individualized high purity colon carcinoma stem cells, methods and use of the same |
| EP3066105A4 (en) * | 2013-11-06 | 2017-10-11 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
| DK3068428T3 (da) * | 2013-11-13 | 2022-10-17 | Univ Minnesota | Annexin-ii-variant-sammensætninger og fremgangsmåder |
| EP3090066A4 (en) * | 2014-01-02 | 2017-08-30 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| CA2950960A1 (en) * | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| KR20170074235A (ko) | 2014-10-31 | 2017-06-29 | 메사추세츠 인스티튜트 오브 테크놀로지 | 면역 세포로의 생체분자의 전달 |
| KR20230030022A (ko) | 2014-11-13 | 2023-03-03 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| BR102015025502B1 (pt) | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| CN107709908A (zh) | 2015-06-29 | 2018-02-16 | 松下知识产权经营株式会社 | 冷藏库 |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| US10612005B2 (en) | 2016-01-08 | 2020-04-07 | Replimune Limited | Modified oncolytic virus |
| MX2018008346A (es) | 2016-01-11 | 2019-07-04 | Turnstone Lp | Terapia de combinación de virus oncológico e inhibidor de punto de control. |
| PL3429618T3 (pl) | 2016-03-16 | 2024-07-01 | Amal Therapeutics Sa | Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie |
| KR20190038480A (ko) | 2016-05-09 | 2019-04-08 | 턴스톤 리미티드 파트너쉽 | 프라임:부스트 병용 요법제 |
| PL417980A1 (pl) | 2016-07-16 | 2018-01-29 | Univ Warszawski | Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu |
| WO2018053508A1 (en) | 2016-09-19 | 2018-03-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
| HUE067838T2 (hu) | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Biontech Us Inc. | Protein antigens and uses thereof |
| WO2019150310A1 (en) | 2018-02-02 | 2019-08-08 | Novartis Ag | Combination of sting agonist and il-15/il15-ra for the treatment of cancer |
| EP3810151B1 (en) | 2018-06-20 | 2025-08-06 | Yale University | Rig-i agonists and treatments using same |
| WO2020010451A1 (en) | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| MX2023002884A (es) | 2020-09-14 | 2023-03-31 | Boehringer Ingelheim Int | Vacuna heterologa de estimulo primario. |
| JP2023545178A (ja) | 2020-10-14 | 2023-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ |
-
2015
- 2015-12-22 US US15/557,653 patent/US20180133327A1/en not_active Abandoned
- 2015-12-22 WO PCT/EP2015/002598 patent/WO2016146143A1/en not_active Ceased
-
2016
- 2016-03-16 PL PL16713731T patent/PL3270957T3/pl unknown
- 2016-03-16 WO PCT/EP2016/000470 patent/WO2016146259A1/en not_active Ceased
- 2016-03-16 AU AU2016232657A patent/AU2016232657B9/en active Active
- 2016-03-16 EP EP16711528.6A patent/EP3270954A1/en active Pending
- 2016-03-16 KR KR1020177029623A patent/KR102212451B1/ko active Active
- 2016-03-16 JP JP2017567525A patent/JP6882207B2/ja active Active
- 2016-03-16 RS RS20200337A patent/RS60089B1/sr unknown
- 2016-03-16 EP EP19219165.8A patent/EP3693009B1/en active Active
- 2016-03-16 CN CN201680015946.2A patent/CN107428845A/zh active Pending
- 2016-03-16 WO PCT/EP2016/000473 patent/WO2016146262A1/en not_active Ceased
- 2016-03-16 AU AU2016232656A patent/AU2016232656A1/en not_active Abandoned
- 2016-03-16 EP EP16711529.4A patent/EP3270955B1/en active Active
- 2016-03-16 NZ NZ733762A patent/NZ733762A/en unknown
- 2016-03-16 WO PCT/EP2016/000472 patent/WO2016146261A1/en not_active Ceased
- 2016-03-16 HR HRP20200491TT patent/HRP20200491T1/hr unknown
- 2016-03-16 CA CA2973747A patent/CA2973747A1/en active Pending
- 2016-03-16 DK DK16713731.4T patent/DK3270957T3/da active
- 2016-03-16 EA EA201792045A patent/EA038049B1/ru unknown
- 2016-03-16 JP JP2017567526A patent/JP6862369B2/ja active Active
- 2016-03-16 CA CA2973770A patent/CA2973770A1/en active Pending
- 2016-03-16 SI SI201630654T patent/SI3270955T1/sl unknown
- 2016-03-16 AU AU2016232659A patent/AU2016232659B2/en active Active
- 2016-03-16 ES ES19219165T patent/ES2978792T3/es active Active
- 2016-03-16 CA CA2973757A patent/CA2973757A1/en active Pending
- 2016-03-16 HU HUE19219165A patent/HUE066851T2/hu unknown
- 2016-03-16 PT PT167115294T patent/PT3270955T/pt unknown
- 2016-03-16 HU HUE16713731A patent/HUE048808T2/hu unknown
- 2016-03-16 PL PL16711529T patent/PL3270955T3/pl unknown
- 2016-03-16 US US15/557,651 patent/US20180133339A1/en not_active Abandoned
- 2016-03-16 US US15/557,647 patent/US20180133295A1/en not_active Abandoned
- 2016-03-16 JP JP2017567527A patent/JP6993240B2/ja active Active
- 2016-03-16 ES ES16711529T patent/ES2781454T3/es active Active
- 2016-03-16 US US15/557,649 patent/US20180133338A1/en not_active Abandoned
- 2016-03-16 PL PL19219165.8T patent/PL3693009T3/pl unknown
- 2016-03-16 WO PCT/EP2016/000471 patent/WO2016146260A1/en not_active Ceased
- 2016-03-16 MX MX2017011796A patent/MX2017011796A/es unknown
- 2016-03-16 HU HUE16711529A patent/HUE048807T2/hu unknown
- 2016-03-16 EP EP16713731.4A patent/EP3270957B1/en active Active
- 2016-03-16 ES ES16713731T patent/ES2781455T3/es active Active
- 2016-03-16 PT PT167137314T patent/PT3270957T/pt unknown
- 2016-03-16 DK DK19219165.8T patent/DK3693009T3/da active
- 2016-03-16 LT LTEP16711529.4T patent/LT3270955T/lt unknown
- 2016-03-16 KR KR1020217003158A patent/KR102386172B1/ko active Active
- 2016-03-16 DK DK16711529.4T patent/DK3270955T3/da active
-
2017
- 2017-07-11 IL IL253416A patent/IL253416B/en unknown
- 2017-07-14 PH PH12017501287A patent/PH12017501287A1/en unknown
- 2017-09-15 CL CL2017002345A patent/CL2017002345A1/es unknown
-
2020
- 2020-04-07 CY CY20201100327T patent/CY1122953T1/el unknown
-
2021
- 2021-03-31 JP JP2021059082A patent/JP7179896B2/ja active Active
- 2021-05-06 JP JP2021078278A patent/JP7190528B2/ja active Active
- 2021-08-01 IL IL285273A patent/IL285273B/en unknown
- 2021-08-06 US US17/396,351 patent/US12178788B2/en active Active
- 2021-08-09 US US17/397,447 patent/US12220450B2/en active Active
- 2021-08-18 AU AU2021218097A patent/AU2021218097B2/en active Active
- 2021-12-09 AU AU2021282506A patent/AU2021282506B2/en active Active
- 2021-12-22 US US17/558,906 patent/US12453762B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509935A5 (https=) | ||
| JP2018510215A5 (https=) | ||
| JP2018509936A5 (https=) | ||
| JP2019528693A5 (https=) | ||
| HRP20200491T1 (hr) | Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma | |
| JP2010516290A5 (https=) | ||
| JP2016501829A5 (https=) | ||
| JP2012500001A5 (https=) | ||
| JP2014502961A5 (https=) | ||
| Liu et al. | Treg suppress CTL responses upon immunization with HSP gp96 | |
| JP2019525753A5 (https=) | ||
| JP2021520818A5 (https=) | ||
| JP2008530975A5 (https=) | ||
| JP2015500827A5 (https=) | ||
| JP2024508683A5 (https=) | ||
| JP2009520758A5 (https=) | ||
| JP2015529677A5 (https=) | ||
| PE20231506A1 (es) | Peptidos y combinaciones de peptidos para su uso en inmunoterapia contra una infeccion por sars-cov-2 (covid-19) | |
| RU2015143164A (ru) | Пептиды kntc2 и содержащие их вакцины | |
| RU2013158399A (ru) | Пептиды sema5b и содержащие их вакцины | |
| JP2010535504A5 (https=) | ||
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| RU2010126154A (ru) | Эпитопные пептиды stat3 | |
| RU2014109137A (ru) | Пептиды mphosph1 и вакцины, включающие их | |
| JP2014133712A5 (https=) |